Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 193, Issue 1-2, Pages 120-129Publisher
ELSEVIER
DOI: 10.1016/j.jneuroim.2007.10.024
Keywords
cannabinoids; experimental autoimmune encephalomyelitis; multiple sclerosis; immunosuppression; neuroprotection
Categories
Funding
- Multiple Sclerosis Society [835] Funding Source: Medline
Ask authors/readers for more resources
Cannabinoids may exhibit symptom control in multiple sclerosis (MS). We show here that cannabinoid receptor (CBR) agonists can also be immunosuppressive and neuroprotective in models of MS. Immunosuppression was associated with reduced: myelin-specific T cell responses; central nervous system infiltration and reduced clinical disease. This was found to be largely CB1R-dependent and only occurred at doses that induced significant cannabimimetic effects that would not be achieved clinically. Lower, non-immunosuppressive doses of cannabinoids however, slowed the accumulation of nerve loss and disability, despite failing to inhibit relapses. This further highlights the neuroprotective potential of cannabinoids to slow the progression of MS. (C) 2007 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available